Mesoglycan: Clinical Evidences for Use in Vascular Diseases

Table 3

Mesoglycan and venous disease.

Author	Study design	Pathology	Patients (𝑛)	Doses/route	Results
Arosio [23]	Randomized	Chronic venous ulcers	183	Mesoglycan 30 mg daily i.m. for 3 weeks then 100 mg daily orally, versus placebo, for 24 ± 1 weeks	Mesoglycan: significant difference in the rate of ulcer healing versus placebo
Andreozzi [24]	Retrospective analysis	Patients with previous DVT	36	Mesoglycan 50 mg twice daily orally	Mesoglycan: effective in preventing thrombotic recurrences
Viliani [25]	Randomized	Mechanical oedema (MO)	44	FKT+Mesoglycan 30 mg twice daily orally versus FKT alone	Mesoglycan: significant clinical improvement in objective and subjective parameters
Prandoni [26]	Randomized	DVT venographically proved	90	Heparin and then oral anticoagulation (12 weeks), then mesoglycan 72 mg daily orally versus placebo, for 1 year	Recurrences of DVT and/or PE less frequent with mesoglycan versus placebo (nonsignificant difference)